Naples-headquartered biotechnology company Enveric Biosciences, which specializes in the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders, agreed to sell one of its cancer-related patent portfolios for an undisclosed amount. Enveric plans to continue to focus and invest in the development of its lead candidates EB-003, a first-in-class neuroplastogen designed to eliminate hallucinations, and EB-002, a next-generation synthetic prodrug of the active metabolite psilocin, company officials said. The patents and applications being sold disclose and claim the synergistic combination of cannabidiol and second therapeutic agents for cancer treatment. The divested portfolio includes patents issued in the U.S., Australia, Canada, China, Europe and Japan, with patent applications pending in Canada, Israel and Korea.